GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange,. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy.
GW has assembled a large in-house team with extensive experience in developing cannabinoids, medicines containing controlled substances, as well as plant-based prescription pharmaceutical products. GW maintains in-house control over all aspects of the cannabinoid product development process - botanical research, extraction technology, formulation into drug delivery technologies, clinical trials and regulatory affairs. GW also holds GMP manufacturing licences for the manufacture of pharmaceutical products for both clinical trials and commercial purposes.
GW’s lead product, Sativex is now approved /recommended for approval in 24 countries. It is indicated as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy. Sativex is also in Phase III clinical development for the treatment of cancer pain, the lead indication for the US market.
GW has now entered into five separate licensing agreements for Sativex – with Bayer HealthCare in the UK and Canada; Almirall in Europe (excluding the UK) and Mexico; Otsuka Pharmaceutical Co. Ltd in the United States; Novartis in the Middle East (excluding Israel), Africa, and Asia (excluding China and Japan); and with Neopharm in Israel.
GW occupies a world leading position in cannabinoid science and has developed an extensive international network of the most prominent scientists in the field. In mid 2007, GW’s early cannabinoid research activities were significantly expanded through the establishment of a global cannabinoid research agreement with Otsuka. Under this collaboration, GW and Otsuka are researching novel cannabinoids as potential treatments in the fields of Central Nervous System (CNS) disorders and oncology. In addition, GW has an in-house programme researching cannabinoids in the field of type 2 diabetes and related metabolic disorders. As part of this programme, GW set up in 2009 the GW Metabolic Research Laboratory at the University of Buckingham.